Stock BPMC BLUEPRINT MEDICINES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
105.6 USD -0.75% Intraday chart for Blueprint Medicines Corporation +2.67% +14.44%
May. 23 Blueprint Medicines Says BLU-222 Combination Well Tolerated for Inhibitor in Type of Breast Cancer MT
May. 23 Blueprint Medicines Corporation to Present the First Promising and Most Advanced Clinical Data for a CDK2 Inhibitor in Combination with an Approved CDK4/6 Inhibitor in HR+/HER2- Breast Cancer at the 2024 ASCO Annual Meeting CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance
AQ
Blueprint Medicines: Q1 Earnings Snapshot
AQ
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
PR
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting
AQ
Blueprint Medicines: Q4 Earnings Snapshot
AQ
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024
PR
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference
PR
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
PR
EC approves treatment for rare haematological disorder
AQ
Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis
PR
EUCOPE Member Spotlight, Q&A with Blueprint Medicines
AQ
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BPMC Stock
  4. News Blueprint Medicines Corporation
  5. Press Releases